Build A Bear Workshop Inc vs Illumina, Inc. — how do they compare? Build A Bear Workshop Inc trades at $36.88 (market cap $467.15M), while Illumina, Inc. trades at $193.06 (market cap $28.96B). The key difference: Illumina, Inc. is far larger — about 62× Build A Bear Workshop Inc's market cap, and Build A Bear Workshop Inc pays a 2.47% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| BBW | ILMN | |
|---|---|---|
Market Cap | $467.15M | $28.96B |
Sector | Consumer Cyclical | Health |
52-Week High | $75.85 | $205.10 |
52-Week Low | $29.84 | $91.00 |
Enterprise Value | $566.59M | $30.32B |
Dividend Yield | 2.47% | — |
Signals from Pluang's Aura AI — not financial advice
Build-A-Bear Workshop (BBW) trades at $36.86, up 6.19% today, with a bullish technical signal and strong analyst support. The stock exhibits attractive valuation metrics, including a P/E of 8.73 and P/S of 0.92, alongside robust profitability with a 10.48% net income margin and 35.87% ROE. Recent earnings have consistently beaten estimates, and the company maintains a debt-free balance sheet while executing a growth strategy focused on international expansion and brand partnerships.
The outlook for BBW is positive, driven by earnings momentum and a consensus price target of $62.50 implying significant upside. Key risks include near-term consumer spending volatility and execution of expansion plans, but strong fundamentals and shareholder returns via dividends support a favorable risk-reward profile for long-term investors.
Illumina (ILMN) trades at $187.96, down 2.97% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows robust profitability with 66.38% gross margins and 18.34% net income margins, though technical indicators suggest near-term bearish pressure. Recent institutional buying activity and positive analyst coverage (51% buy ratings) support the stock's long-term growth narrative in the genomics sector.
The outlook remains positive with a consensus price target of $201.58 representing 7% upside potential. Key catalysts include continued NovaSeq X adoption and AI partnerships, while risks involve competitive pressures and execution challenges in achieving projected revenue growth. The company's turnaround from net losses to $850M profit in 2025 demonstrates improved operational efficiency.
Trailing returns across standard periods
Build-A-Bear is a global retailer specializing in customizable stuffed animals. It offers an interactive make-your-own experience where customers choose, stuff, and dress their furry friends in-store or online.
Read more on BBW →Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →